Ключ. слова: bone and soft tissue sarcoma, advanced disease, advanced disease, high-dose ifosfamide
Індекс рубрикатора НБУВ: Р562.3-52

Рубрики:

Саркома

Шифр НБУВ: Ж14160 Пошук видання у каталогах НБУВ 

Ключ. слова: advanced disease, cisplatin, colorectal carcinoma, dacarbazine, irinotecan
Індекс рубрикатора НБУВ: Р569.433.34-52

Рубрики:

Пухлини прямої кишки

Шифр НБУВ: Ж14160 Пошук видання у каталогах НБУВ 

Індекс рубрикатора НБУВ: Р569.133.1

Рубрики:

Пухлини молочних (грудних) залоз

Шифр НБУВ: Ж14160 Пошук видання у каталогах НБУВ 

Aim - Kikuchi - Fujimoto disease (KFD) or histiocytic necrotizing lymphadenitis is a rare disorder and often confused with lymphoma. There is presented a case of 28-year-old patient with cervical lymphadenopathy, who had history of lymphoma. On immunohistopathologic examination diagnosis of KFD was made and patient followed without any treatment. Conclusion: patient's lymphadenopathy had almost resolved and he was completely asymptomatic after three months. In patient with cervical lymphadenopathy KFD should be considered in the differential diagnosis.

Breast cancer is the most common female malignant disease in the western countries where a woman's lifetime risk of developing the disease is more than 10 %. Nulliparity or use of hormonal replacement therapy, strong family history, or a history of therapeutic thoracic radiation are considerable high risk factors for the development of breast cancer. Nowadays more new effective therapeutic agents have been developed for the intervention of the breast cancer, but prognosis is still remained poor in the metastatic disease. For the general population, screening mammography in women older than 40 - 45 years has been shown to be effective in identifying early-stage breast cancer and in decreasing the mortality rate. In randomized screening mammography trials for breast cancer, it has been established that screening mammograms reduced breast cancer mortality in women older than 50 years of age by 25 to 30%. This review article summarizes the risk factors for developing breast cancer, methods for risk assessment and the accepted screening guidelines.

According to the analysis on locally advanced breast cancer (LABC) from all breast cancer cases recorded in Surveillance Epidemiology and End Results database between the years 1992 - 1999 in the United States, the incidence of LABC were found to be 4,6 % of all female breast cancers. Clinically, when breast cancer has advanced locoregionally but has not yet spread outside of the breast and regional lymph nodes, it is considered LABC. LABC includes breast cancers that have evidence of a large mass, involve the skin of the breast or the underlying muscles of the chest wall, and cancers that have infiltrated into the local lymph nodes. The prognosis of patients with LABC is relatively poor, with 5-year survival rates less than 50 %. Because the incidence of LABC is very low, there are not many studies comparing neoadjuvant chemotherapy regimens in the literature. In management of LABC, initial therapy should be systemic neoadjuvant chemotherapy, aiming pCR. Anthracycline-based chemotherapy regimens are frequently recommended as the standard primary neoadjuvant chemotherapy for the treatment of LABC. Today the optimal duration of neoadjuvant chemotherapy is unknown. Neoadjuvant endocrine therapy is considered an option for patients with honnone receptor-positive LABC. Ongoing clinical trials are now under way to evaluate the use of novel targeted agents in the neoadjuvant treatment of LABC.

Індекс рубрикатора НБУВ: Р56-3 + Р410.230.35

Рубрики:

Онкологія

Тромбоз і емболія вен

Шифр НБУВ: Ж14160 Пошук видання у каталогах НБУВ